National Institute on Aging invests an additional $7.3 million into NU-9
National Institute on Aging invests an additional $7.3 million into NU-9
November 6, 2024
This funding will support research into the potential of the ALS drug NU-9 for treating other neurodegenerative diseases. Invented by Richard Silverman, NU-9 targets underlying disease mechanisms rather than focusing solely on symptoms. This approach raises scientists' hopes that NU-9 could prove effective against the common pathways that drive multiple neurodegenerative diseases.
